GenSight Biologics S.A. (FRA:G49N)

Market Cap	27.67M +6.4%
Revenue (ttm)	652.00K -75.2%
Net Income	-12.04M
EPS	-0.08
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1070
Previous Close	0.1092
Day's Range	0.1070 - 0.1070
52-Week Range	0.0588 - 0.2250
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 29, 2026

About GenSight Biologics

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 13
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: G49N

Financial Performance

In 2025, GenSight Biologics's revenue was 652,000, a decrease of -75.16% compared to the previous year's 2.63 million. Losses were -12.04 million, -14.03% less than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error